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Introduction: Intrauterine growth restriction complicates 5e10% of pregnancies. This study aims to test
the hypothesis that Chinese herbal formula, JLFC01, affects pregnancy and fetal development by
modulating the pro-inﬂammatory decidual micro-environment.
Methods: Human decidua from gestational age-matched elective terminations or incomplete/missed
abortion was immunostained using anti-CD68 þ anti-CD86 or anti-CD163 antibodies. qRT-PCR and
Luminex assay measured the effects of JLFC01 on IL-1b- or TNF-a-induced cytokine expression in ﬁrst
trimester decidual cells and on an established spontaneous abortion/intrauterine growth restriction
(SA/IUGR)-prone mouse placentae. The effect of JLFC01 on human endometrial endothelial cell angio-
genesis was evaluated by average area, length and numbers of branching points of tube formation. Food
intake, litter size, fetal weight, placental weight and resorption rate were recorded in SA/IUGR-prone
mouse treated with JLFC01. qRT-PCR, Western blot and immunohistochemistry assessed the expres-
sion of mouse placental IGF-I and IGF-IR.
Results: In spontaneous abortion, numbers of decidual macrophages expressing CD86 and CD163 are
increased and decreased, respectively. JLFC01 reduces IL-1b- or TNF-a-induced GM-CSF, M-CSF, CeC
motif ligand 2 (CCL2), interferon-g-inducible protein-10 (IP-10), CCL5 and IL-8 production in ﬁrst
trimester decidual cells. JLFC01 suppresses the activity of IL-1b- or TNF-a-treated ﬁrst trimester decidual
cells in enhancing macrophage-inhibited angiogenesis. In SA/IUGR-prone mice, JLFC01 increases
maternal food intake, litter size, fetal and placental weight, and reduces fetal resorption rate. JLFC01
induces IGF-I and IGF-IR expression and inhibits M-CSF, CCL2, CCL5, CCL11, CCL3 and G-CSF expression in
the placentae.
Discussion: JLFC01 improves gestation by inhibiting decidual inﬂammation, enhancing angiogenesis and
promoting fetal growth.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
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Ltd. This is an open access article u1. Introduction
Spontaneous abortion (SA) complicates 15% of human preg-
nancies. Although chromosomal anomalies account for more than
50% of SA, abnormal fetal development, maternal systemic disor-
ders and environmental insults contribute to its incidence [1]. The
mechanisms causing SA remain unknown thereby precluding the
development of effective prevention and treatment. Various at-
tempts including immunological approaches [2e6] have notnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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herbal medicine (CHM) has been widely used in Asia for centuries.
Although studies suggest that CMH prevents SA [7], evidence is
insufﬁcient to assess the effectiveness of CHM in treating SA. First
appearing in Chung-Ching Chang's “Synopsis of Golden Chamber”
about 1800 years ago, JLFC01 is derived from a traditional Chinese
formula that successfully treats blood stagnation.
Intrauterine growth restriction (IUGR) complicates 5e10% of
pregnancies [8]. Many studies indicate that preeclampsia and IUGR
[9] are initiated in the ﬁrst trimester as a consequence of insufﬁ-
cient uteroplacental blood ﬂow to the developing fetal-placental
unit and suggest a similar origin for SA. Blastocyst-derived semi-
allogeneic extravillous trophoblasts (EVTs) traverse the decidua
and inner third of the myometrium and interact with resident
decidual cells, decidual natural killer (NK) cells and macrophages.
Invading EVTs transform uterine spiral arteries into high-
capacitance vessels accompanied by expression of angiogenic
factors and microvascular angiogenesis [10]. The resulting
increased uterine blood ﬂow to the intervillous space is pivotal for
fetal-placental development [9,11]. Disturbances of this environ-
ment disrupt early fetal development and elicit long-term
complications in affected children.
An aberrant pro-inﬂammatory decidual micro-environment
elicits preeclampsia, SA and IUGR. In addition to mediating spiral
artery transformation, decidual macrophages are critical modula-
tors of the immune balance at the fetalematernal interface. The
function, differentiated state and responsiveness of macrophages
are governed by their micro-environment and proximity to
adjacent cells [12,13]. Generally, macrophage polarization is
divided into classically (M1) and alternatively (M2) activated
groups [14]. Besides bridging both innate and adaptive immunity,
which defend against pathogens, decidual macrophages are
important mediators of implantation, placental development and
cervical ripening [15]. In early pregnancy, M2 macrophages play a
key role in inducing immunotolerance of the fetal semi-allograft
[15]. Tight regulation of macrophage trafﬁcking/function plays
crucial roles during placentation. Under physiological steady state,
macrophages isolated from ﬁrst trimester decidua are polarized
toward an immunotolerant M2 phenotype [16]. By contrast,
pro-inﬂammatory M1 polarization of macrophages is linked to
adverse pregnancy outcomes [17]. Our studies indicate that potent
pro-inﬂammatory cytokines, IL-1b and TNF-a, stimulate human
ﬁrst trimester decidual cells (FTDCs) to secrete several chemokines
that recruit NK cells [18] andmonocytes [19e21]. The decidual cells
then promote macrophage differentiation toward an M1 subtype
via the regulation of colony-stimulating factors [13].
The current study postulates that these decidual M1 macro-
phages are integral to the onset of SA and proposes to treat and/or
prevent SA by counteracting the resulting pro-inﬂammatory
decidual milieu. Initial observations determined that unlike the
dominant M2 immunotolerant macrophage population of normal
ﬁrst trimester human decidua, the decidualmacrophage population
accompanying SAs displays a pro-inﬂammatory M1 phenotype.
Complementing these in situ observations, themodulating effects of
JLFC01 on: 1) IL-1b- or TNF-a-induced expression of several cyto-
kines by FTDCs; 2) FTDCs in modulating human endometrial
endothelial cell (HEEC) angiogenesis-inhibiting activity of macro-
phages were examined. These in vitro observations were extended
to include CBA/J x DBA/2J mice, an established SA/IUGR-prone
model, in which the effects of JLFC01 ingestion were assessed. An
aberrant decidual pro-inﬂammatory micro-environment [22] can
also interfere with normal fetal growth by disrupting fetal pro-
gramming. The insulin-like growth factors (IGFs) and their receptors
are potent regulators of protein turnover, mitogenesis and differ-
entiation [23] and implicated in fetal-placental development [24].Abnormal IGF expression, malfunctioning IGF receptors or defective
downstream signaling pathways are proposed to contribute to the
development of IUGR [25]. Thus, the effects of JLFC01 ingestionwere
compared on placental expression of mRNA and protein levels of
IGFs and their receptors in SA/IUGR-prone mice.
2. Methods
2.1. Immunoﬂuorescent staining of decidua for macrophage markers
Decidua was obtained under Institutional Review Board (IRB) approval at
Mackay Memorial Hospital, Taipei, Taiwan. Gestational age (GA)-matched tissue was
obtained from elective terminations of normal pregnancies between 6 and 12 weeks
of gestation without uterine contraction, vaginal bleeding or evidence of fetal
demise. Upon diagnosis of missed/incomplete abortion, decidual basalis was evac-
uated within 24 h from patients without infection or systemic diseases. Serial sec-
tions of OCT-embedded specimens were immunostained with mouse anti-human
CD68 (1:25, Dako, Carpinteria, CA) followed by Rhodamineeconjugated donkey
anti-mouse antibody (1:50, EMD Millipore, Billerica, MA). Sections were then
incubated with rabbit anti-human CD163 (1:250, SigmaeAldrich, St. Louise, MO) or
CD86 (1:200, GeneTex, Irvine, CA) followed by corresponding FITCeconjugated
secondary antibody (1:100) and 40 ,60-diamidino-2-phenylindole (1:500,000, Sig-
maeAldrich). Morphometric analysis of cell numbers used Axiovision 3.1 software
(Carl Zeiss, Oberkochen, Germany). Five randomly selected ﬁelds from each section
(three sections/tissue) were examined. Cell numbers per ﬁeld (3  106 pixel2) were
counted and calculated as themean of 15 ﬁelds for each tissue. A total of 15 cases per
group were examined.
2.2. Cell isolation and culture
FTDCs were isolated and cultured as previously described [20]. Brieﬂy, decidua
fromelective termination of 6e12weeks gestationwasobtainedunder IRB approval at
The Ohio State University (OSU) and Beth Israel Medical Center, New York, NY. Cells
were puriﬁed using Ficoll-Hipaque Plus (GEHealthcare, Piscataway, NJ). CD45 staining
conﬁrmed the absence of leukocytes. Cultured FTDCs were found to be vimentin-
positive and cytokeratin-negative and displayed morphological changes and
enhanced prolactin and plasminogen activator inhibitor-1 as well as inhibited inter-
stitial collagenase and stromelysin-1 expression with prolonged tissue factor
expression during incubation with a progestin. Conﬂuent FTDCs were primed with
estradiol (108 M) þ medroxyprogesterone acetate (107 M) for 7d and pre-treated
with or without 1.25 mg/ml of a Chinese herbal formula, JLFC01, for 24 h then incu-
batedwith 1ng/ml of IL-1bor TNF-a (R&DSystems,Minneapolis,MN)with orwithout
JLFC01. JLFC01 was manufactured from herbs and processed in stainless steel extrac-
tors at a low temperature (below 100 C) in order to preserve the activity of essential
ingredients and generate a water decoction. This procedure follows the sequence
described in canonical Chinese medicine book since the sequence of the herbs pro-
cessed within a decoction determines the efﬁcacy of the formula. The extracted liquid
is then spray dried to form a powder. This procedure follows good manufacturing
practice (GMP) guidelines. In addition, both the presence and levels of heavy metal
and microbes are also assessed. Conditioned medium (CM) supernatants were
collected.Monocyteswere isolated from peripheral blood of healthy reproductive age
female donorsusing Ficoll-Hipaque andpuriﬁedusing anti-CD14-paramagnetic beads
according to the manufacturer's instructions (Miltenyi Biotec, Auburn, CA).
For HEECs [26], blood vessels in the endometrium obtained from hysterectomy
for myomas was dissected, then, minced and digested with type VII collagenase/
dispase/DNase I followed by ﬁltration through a 70-mm cell strainer. The cells was
labeled with biotinylated UEA-1 (Ulex europaeus) lectin, and then, separated from
non-labeled cells by panning on activated surface/AIS MicroCELLector ﬂasks coated
with streptavidin. Cells were cultured in EBM-2 medium supplemented with 15%
fetal calf serum.
2.3. Cell proliferation assay
Cell proliferation was examined using a CellTiter 96 One Solution Cell Prolifer-
ation Assay (Promega, Madison, WI). Brieﬂy, FTDCs were treated with vehicle, 0.08,
0.16, 0.31, 0.63, 1.25, 2.5, 5 or 10 mg/ml of JLFC01 for 48 h. Absorbance was detected at
490 nm after adding MTS reagent.
2.4. Bio-Plex assay
Bio-Plex assays (Bio-Rad, Hercules, CA) measured GM-CSF, M-CSF, CeC motif
ligand 2 (CCL2), interferon-g-inducible protein-10 (IP-10), CCL5 and IL-8 levels in CM
from FTDC cultures as well as M-CSF, CCL11, CCL2, CCL3, CCL5 and G-CSF levels in
mouse placenta lysates. Data acquisition and analyses were completed with the Bio-
Plex 200 system using Bio-Plex Manager Software v6. Bicinchoninic acid protein
assay (Thermo scientiﬁc, Rockford, IL) measured total cell protein levels.
2.5. Quantitative RT-PCR (qRT-PCR)
Total RNA was extracted using total RNA puriﬁcation plus kit (Norgen Bioteck,
ON, Canada). Reverse transcription used SuperScript™III First-Strand Synthesis
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Fig. 1. Macrophages polarized toward M1 subtype in the decidua from patients with
SA. Representative photomicrographs of immunoﬂuorescent staining of M1
macrophage markers, (A, B), CD86 (green) and M2 macrophage marker, (C, D) CD163
(green), in decidua from GA-matched elective terminations and patients with SA.
These tissues were co-stained with anti-CD68 antibody (red). Arrows indicate
macrophages expressing CD86 or CD163 (yellow or orange). Morphometric analysis
determined the average numbers of (E) CD68þCD86þ cells and (F) CD68þCD163þ cells.
Cell numbers/ﬁeld were calculated as the mean of 15 ﬁelds (3 sections/tissue, 5 ﬁelds/
section). The results are reported as mean ± SEM. n ¼ 15; *p < 0.05, ***p < 0.005;
magniﬁcation: 400x; Scale bar: 50 mm.
L. Piao et al. / Placenta 36 (2015) 559e566 561System from Invitrogen. Speciﬁc primer sets for human GM-CSF, M-CSF, CCL2, IP-10,
CCL5, IL-8 or b-actin and mouse M-CSF, CCL11, CCL2, CCL3, CCL5, G-CSF or b-actin
(Integrated DNA technologies, Coralville, IA) (Supplementary Table 1) were used for
qPCR using SYBR® green-based detection. Quantitation of unknowns was deter-
mined and adjusted to quantitative expression of b-actin in the speciﬁc samples.
Melting curve analysis determined the speciﬁcity of the ampliﬁed products and the
absence of primer-dimer formation.
2.6. Angiogenesis assays
CM from FTDCs was treated with anti-IL-1b or anti-TNF-a neutralizing antibody
(R & D Systems) followed by protein G-sepharose (SigmaeAldrich, St. Louise, MO)
treatment. Macrophages were ﬁrst cultured with CM from FTDCs ± JLFC01 ± IL-1b or
TNF-a for 2d and then co-cultured with HEECs for 8 h. To test whether JLFC01 had a
direct effect on angiogenesis, macrophages were incubated with CM from FTDCs
without JLFC01 treatment for 2d followed by co-culture with HEECs
pretreated± 1.25 mg/ml JLFC01 for 8 h. The culture wells were coated with growth
factor-reduced Matrigel (BD Biosciences, San Jose, CA). Tube formationwas assessed
by measuring average area, length and number of branching points using AngioTool
software (NCI) [27].
2.7. Mouse studies
Studies were performed under OSU Institutional Animal Care and Use Com-
mittee approval. Eight-week-old virgin female CBA/J mice were treated with
0.3 gm/kg body weight/d of JLFC01 dissolved in ddH2O, compared to 1e2 gm/d for
human, based on the manufacturer's recommendation or ddH2O by oral gavage for
7d before mated with 10-week-old male DBA/2J mice (The Jackson Laboratory, Bar
Harbor, ME). Sighting a vaginal plug was designated as gestational day 0 (GD0). The
treatment was continued until sacriﬁce on GD15. Maternal food intake, litter size,
placental and fetal weight, and the numbers of fetal resorption were recorded.
2.8. Immunohistochemistry of mouse placental IGF-I & IGF-IR
Deparafﬁnized formalin-ﬁxed sections were incubated with goat serum (Lab-
Vision, Fremont, California), then, rabbit anti-IGF-I (1:2,400, Aviva System Biology,
San Diego, CA), Anti-IGF-IR antibody or IgG isotype (1:2,400, Cell Signaling Tech-
nology, Beverly, MA). Biotinylated goat anti-rabbit antibody (1:400, Vector Labora-
tories, Burlingame, CA) was added. The antigeneantibody complex was detected
using a streptavidineavidinebiotineperoxidase kit and 3,3-Diaminobenzidine tet-
rahydrochloride dihydrate (Vector Laboratories) with hematoxylin counterstaining.
2.9. Statistics
The variance and normality of data from immunoﬂuorescent staining, qRT-PCR,
Luminex assay, angiogenesis assay, mouse studies, densitometry and H-scores of
immunohistochemistry were ﬁrst examined. Then, the statistical signiﬁcance of
results with equal variance was examined by t-test assuming equal variance. The
results with unequal variance that either passed or failed normality test were then
evaluated by t-test assuming unequal variance or theManneWhitney rank sum test,
respectively. Generalized estimating equation assessed statistical signiﬁcance of
mouse food intake. A p < 0.05 was considered signiﬁcant.
3. Results
3.1. Macrophages polarize toward M1 subtype in ﬁrst trimester
decidua from SA
Co-localization of anti-CD68 (macrophage marker, red) with
either anti-CD86 (M1 marker, green) or anti-CD163 (M2 marker,
green) is indicated by yellow-orange immunoﬂuorescence. Fig. 1
indicates that FTDCs also express the CD86 and CD163. Compared
to GA-matched controls (Fig. 1A, C), SA-derived decidua displays
signiﬁcant higher numbers of CD86-positive pro-inﬂammatory M1
macrophages (Fig. 1B, E) and lower numbers of tolerogenic CD163-
positive M2 macrophages (Fig. 1D, F) (n ¼ 15).
3.2. JLFC01 inhibits IL-1b- or TNF-a-induced cytokine production in
FTDCs
MTS assay shows that FTDC proliferation was suppressed by
JLFC01 at concentrations greater than 1.25 mg/ml (Supplementary
Figure 1). Therefore, to eliminate these potential confounding
anti-proliferation effects in subsequent in vitro experiments, FTDCs
were pre-incubated with 1.25 mg/ml of JLFC01 for 24 h and then
treated with IL-1b or TNF-a for an additional 24 h.Fig. 2 shows profound enhancement by either IL-1b or TNF-a of
mRNA expression of several pro-inﬂammatory cytokines was
blunted during co-incubation with JLFC01 (n ¼ 3e11,
Supplementary Table 2). Speciﬁcally, IL-1b and TNF-a induced
GM-CSF expression by 4.5- and 10.19-fold, respectively. This in-
duction was correspondingly reduced by 51% and 81% by JLFC01
treatment (Fig. 2A). M-CSF expression enhanced by IL-1b
(6.34-fold) or TNF-a (4.21-fold) was suppressed by 55% and 56%,
respectively, by JLFC01 (Fig. 2B). Fig. 2C demonstrates that IL-1b
elicited a 24.99-fold and TNF-a up-regulated a 15.74-fold increase
of CCL2 expression. JLFC01 treatment decreased this activation by
49% (by IL-1b) and 45% (by TNF-a) though inhibition of TNF-
a-induced CCL2 expression only attained borderline statistical
signiﬁcance. For IP-10 expression, Fig. 2D indicates a 6.39- and
10.04-fold increase by IL-1b and TNF-a, respectively. JLFC01 corre-
spondingly inhibited IL-1b- and TNF-a-stimulated IP-10 expression
by 53% and 79%. The expression of CCL5 and IL-8 was promoted in
response to IL-1b by 3.58- and 5483.77-fold, respectively, whereas
JLFC01 suppression of this induction only attained borderline
statistical signiﬁcance. However, JLFC01 signiﬁcantly repressed
TNF-a-induced CCL5 (8.37-fold) and IL-8 (326.60-fold) expression
by 91% and 63%, respectively (Fig. 2E, F).
In parallel incubations, protein expression levels of GM-CSF,
M-CSF, CCL2, IP-10, CCL5 and IL-8 were measured by Bio-Plex
assays (Fig. 2GeL, n ¼ 3e11, Supplementary Table 2). In FTDCs,
IL-1b induced GM-CSF, M-CSF, CCL2, IP-10, CCL5 and IL-8 pro-
duction by 7.5-, 8.78-, 52.9-, 734.9, 545.9- and 186.2-fold,
respectively. JLFC01 suppressed this induction by 62%, 56%, 17%,
98%, 91% and 38%, respectively. Similarly, GM-CSF, M-CSF, CCL2, IP-
10, CCL5 and IL-8 production was up-regulated by TNF-a by 1.3-,
6-, 47.6-, 982-, 474- and 115-fold with JLFC01 treatment sup-
pressing this enhancement by 69%, 44%, 52%, 97%, 93% and 61%,
respectively.
Fig. 2. JLFC01 inhibits IL-1b- (EMI) or TNF-a- (EMT) induced GM-CSF, M-CSF, CCL2, IP-10, CCL5 and IL-8 expression in FTDCs. (AeF) The mRNA expressionwas measured by qRT-PCR.
(GeL) The protein levels of each individual cytokines in CM from leukocyte-free FTDCs were measured by multiplex Luminex assay and normalized to total cell protein. The results
are reported as mean ± SEM. n ¼ 3e 11; *: vs. EM, #: vs. EMI or EMT. * or #p < 0.05, ** or ##p < 0.01, *** or ###p < 0.005.
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in enhancing angiogenesis-inhibiting activity of macrophages
To test potential interactions among different cell types,
macrophage-regulated angiogenesis was determined by ﬁrst
incubating macrophages with CM from IL-1b- or TNF-a-stimulated
FTDCs ± JLFC01 followed by co-culturing with HEECs in an angio-
genesis assay. Direct effects of JLFC01 on HEECs were also assessed
by co-culturing macrophages treated with CM from IL-1b- or TNF-
a-stimulated FTDCs and JLFC01-treated HEECs in an angiogenesis
assay (n ¼ 4). Fig. 3A indicates average tube area was increased by
macrophages incubated with CM derived from FTDCs treated with
IL-1b or TNF-a, while JLFC01 blocked the effects. Consistently, other
angiogenesis measurements, i.e. tube length (Fig. 3B) and number
of branching points (Fig. 3C), were reduced by macrophages incu-
bated with CM from FTDCs treated with IL-1b or TNF-a.
Co-incubation of FTDCs with JLFC01 reversed this effect. However,
JLFC01 treatment of HEECs did not affect any of the three param-
eters (Fig. 3A, B, C) in HEECs co-cultured with macrophages
pre-incubated with CM from IL-1b- or TNF-a-stimulated FTDCs.
3.4. JLFC01 prevents placental pro-inﬂammatory cytokine
production, miscarriage and improves fetal-placental growth as well
as maternal food intake in SA/IUGR-prone mice
JLFC01 ingestion: i) inhibits placental expression of M-CSF
(Fig. 4A and G), CCL11 (Fig. 4B and H), CCL2 (Fig. 4C and I), CCL3
(Fig. 4D and J), CCL5 (Fig. 4E and K) and G-CSF (Fig. 4F and L)
(mRNA: 1.96 x, 5.96x, 618.39x, 1.93x, 3.37x and 5.36x, respectively,n ¼ 5 - 8; protein: 1.40x, 2.07x, 74.69x, 2.11x, 1.29x and 1.50x,
respectively, n ¼ 18 - 20); ii) increased litter size (Fig. 5A), fetal
(Fig. 5B) and placental weight (Fig. 5C) by 35.56%, 50.92% (from 1.86
to 2.80 gm) and 28.20% (from 356.5 to 438.7 mg), respectively,
accompanied by a 40.44% fetal resorption rate reduction (Fig. 5D);
iii) increased food intake by 19.6%, 10.8% and 27.8% at GD5, GD10
and GD15, respectively (Fig. 5E) (n ¼ 3). Potential mechanisms
responsible for increased fetal growth accompanying JLFC01
ingestion were examined by placental IGF-I and IGF-IR expression.
Steady state mRNA levels of IGF-I and IGF-IR are up-regulated by
JLFC01 treatment by 2.2- and 2.1-fold, respectively (Fig. 6A and B),
with Western blot revealing parallel effects on IGF-I and IGF-IR
protein expression (Fig. 6C and D) (n ¼ 3). Immunohistochem-
istry demonstrates that IGF-I (Fig. 6F and I) and IGF-IR (Fig. 6H and
J) expression in the placentae are consistently enhanced by JLFC01
ingestion (n ¼ 3).
4. Discussion
Successful pregnancy and adequate fetal growth require main-
tenance of homeostasis and immune balance at the maternalefetal
interface. Conditions disrupting this equilibrium are implicated in
eliciting shallow placentation accompanied by SA, IUGR and pre-
eclampsia. These human pregnancy complications are associated
with induction of depression, stress, anxiety and lower self-esteem
in affected couples, while imposing a ﬁnancial burden on affected
families and society [28]. The pathogenesis of SA and IUGR are
multi-factorial with the underlying mechanisms poorly under-
stood. Immunological [2], nutritional [29], hormonal [30], and
Fig. 3. JLFC01 suppresses the activity of IL-1b- (EMI) or TNF-a- (EMT) treated FTDCs in enhancing angiogenesis-inhibiting activity of macrophages. HEECs treated with or without
JLFC01 co-cultured with macrophages incubated with CM from IL-1b- or TNF-a-treated FTDCs in the presence or absence of JLFC01 were grown on Matrigel for 8 h. Angiogenesis
was assessed by measuring (A) average area (mm2), (B) length (mm) and (C) numbers of branching points (5 random ﬁelds/well). The results are reported as mean ± SEM. n ¼ 4; *: vs.
EM, #: vs. EMI or EMT. ##p < 0.01, *** or ###p < 0.005.
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treating SA and IUGR.
JLFC01 used in this study was modiﬁed from a traditional for-
mula, Guizhi Fuling Wan, containing the same herbs described in
canonical Chinese medicine books. However, the dosages and
extracting procedures vary among different pharmaceutical com-
panies and can potentially affect the efﬁcacy. Therefore, JLFC01 was
chosen as the name of this preparation manufactured by Brion
Research Institute to avoid confusion. Despite centuries long use in
Asia of JLFC01 to effectively treat SA with minimal side effects, theFig. 4. JLFC01 inhibits M-CSF, CCL11, CCL2, CCL3, CCL5 and G-CSF expression in placentae fr
The protein levels of each individual cytokines in placentae from mice with SA/IUGR were m
reported as mean ± SEM. n ¼ 5e8 for qRT-PCR; n ¼ 18e20 for Bio-Plex assay. *p < 0.05, **mechanisms and components in the herbs responsible for its
actions are understudied and consequently not understood. To
elucidate this question, the current study integrates in vitro ob-
servations on primary human cells with in vivo observations on an
SA/IUGR-prone mouse model. The latter demonstrates that JLFC01
induces novel effects by improving growth of the fetal-placental
unit and increasing maternal food intake, thus complementing its
historical effectiveness in preventing SA. Initial assessment by
immunoﬂuorescent staining revealed that, consistent with a local
pro-inﬂammatory milieu, ﬁrst trimester decidual macrophages areom mice with SA/IUGR. (AeF) The mRNA expression was measured by qRT-PCR. (GeL)
easured by multiplex Bio-Plex assay and normalized to total cell protein. The results are
p < 0.01, ***p < 0.005.
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found that stimulation of FTDCs with TNF-a- or IL-1b enhances
macrophage-induced EVT apoptosis as well as decidual macro-
phage and dendritic cell recruitment/activation [13,20,21]. These
observations implicate TNF-a- and IL-1b-stimulated decidual cells
in the pathogenesis of pregnancy complications [13]. In the current
study, incubation of FTDCs with JLFC01 inhibited both TNF-a- and
IL-1b-induced production of cytokines associated with monocyte
and NK cell recruitment and activation, suggesting that JLFC01
improves pregnancy outcomes and fetal growth by exerting broad
anti-inﬂammatory activities. Consistently, JLFC01 treatment
suppressed mouse placental production of pro-inﬂammatory cy-
tokines, suggesting an association with its roles in improving
pregnancy and fetal growth.
EVT invasion of the decidua and underlying myometrium acting
in concert with robust angiogenesis are critical to successful
placentation. In addition to leukocyte recruitment and activation,
speciﬁc cytokines up-regulated by IL-1b or TNF-a in FTDCs were
shown to exert mixed angiogenic effects. Speciﬁcally, GM-CSF,
M-CSF and IL-8 promote [32], whereas IP-10 suppresses [33],
angiogenesis and endothelial cell proliferation. Moreover, IL-8 in-
hibits [34], while CCL2 and IP-10 [33,35] increase, endothelial cell
apoptosis. The net effect of JLFC01 on secreted angiogenesis-
regulating cytokines by FTDCs under the modulating inﬂuence of
IL-1b or TNF-a has yet to be determined. Moreover, in early preg-
nancy, decidual macrophages and FTDCs are positioned to affect
angiogenesis [36,37]. The current use of primary HEECs to test
angiogenesis found that CM derived from IL-1b- or TNF-a-treated
FTDCs enhances the angiogenesis-inhibiting activity of macro-
phages. However, treatment of FTDCs with JLFC01 reverses this
effect, suggesting that JLFC01 improves placentation by promoting
decidual angiogenesis. The current study used blood drawn from
non-pregnant healthy reproductive age women. Ideally, blood, ﬁrst
trimester decidual cells and HEECs should all be obtained from the
same woman receiving elective termination. However, both ethical
proscriptions and varying locations of sample collection present a
major practical obstacle in obtaining blood as well as sufﬁcient
tissue for the isolation of decidual cells and HEECs from the same
patient. Thus, in recruiting the donors for blood and tissue, cells
were isolated from individuals with similar physiological charac-
teristics using the same inclusion/exclusion criteria.
In addition to implantation, JLFC01 may aid pregnancy by
directly targeting the embryo and/or by modifying fetal program-
ming to improve fetal growth. Critical windows of developmental
plasticity are initiated pre-conceptually and extend through early
postnatal life [38]. Fetal programming encompasses the role of
developmental plasticity in response to environmental and nutri-
tional signals during early life and its potential adverse conse-
quences in later life [38]. The maternal contribution to the
nutritional, hormonal and metabolic fetal environment is crucial to
fetal growth [39]. Disturbances in related mechanisms can impede
early fetal development with potential long-term outcomes and
pregnancy complications [39]. Increasing evidence indicates an
association of such fetal growth pathologies as IUGR and small-for-
gestational-age fetuses with changes in placental transporter
function [39]. Previous attention has generally focused on the
molecular mechanisms underlying programming effects with the
goal of development of targeted therapy in the population at risk
[40].
Decreased maternal serum IGF-I levels are suggested to be
associated with poor placental function, but not low birth weight
[41]. Both IGF-I and IGF-II play crucial roles in fetal-placental
growth throughout pregnancy [42]. However, previous studies
provide conﬂicting results. Speciﬁcally, IGF-I and IGF-II expression
levels are increased in term placentae associated with IUGR [43],whereas immunohistochemistry studies revealed conserved dis-
tribution of the IGF-I receptor in placentae from normal pregnan-
cies and pregnancies associated with IUGR [44]. Although
inconsistent with results from other studies [43], the increase of
placental IGF-I and IGF-1R accompanying increased fetal and
placental weight by JLFC01 in the SA/IUGR-prone mice used in the
current study indicates an association of IGF-I with fetal growth
that is regulated by JLFC01. These conﬂicting observations suggest a
need to test the direct effects of JLFC01 on the embryo. Moreover,
the current study found that JLFC01 improves maternal food intake
in pregnant mice prone to SA/IUGR, thus, mandating further in-
vestigations of the regulation of nutrient transport machinery at
the maternalefetal interface by JLFC01.
In summary, the centuries-long use of JLFC01 to treat such
diverse ailments as blood stagnation and threatened abortion attest
to its unprecedented safety record. This study conﬁrms its protec-
tive effects during gestation and reveals a novel effect on fetal
development. The current ﬁndings also suggest mechanisms that
maintain pregnancy and improve fetal growth. Further studies are
required to uncover critical regulatory mechanisms by which
JLFC01 prevents SA by focusing on key processes necessary to
maintain pregnancy at the implantation site, i.e. angiogenesis,
macrophages polarization, and fetal programming and the active
components of JLFC01. In addition to FTDCs, HEECs and macro-
phages, other cell types in the decidua, including various immune
cells, vascular smooth muscle cells, EVTs, and glandular cells may
also be targets for JLFC01, indicating the need to test the effects of
JLFC01 on these cell types.
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